ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VCYT / forecast
CDNA (71) CELC (31) CON (68) BLLN (70) ⌘ Pro Terminal →

Veracyte Inc. (VCYT) 12-Month Stock Forecast & Price Target Cone

$49.00 -2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $48.94

Veracyte Inc. (VCYT) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (70.1% gross margin, 5% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $4.02B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VCYT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $49.00 (-2.02% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, VCYT ranks #49 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VCYT compare to CDNA and CELC in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VCYT?
▼

Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $48.94 (-0.12%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 24.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510073
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Cash (14)Whales (16)SEC (18)Macro (14)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
$64 Bull$52 Base$40 Bear
📬 FREE VCYT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCYT)Realized 20D OHLCV Swing Band: ±10.6%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY VCYT SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)

20D Institutional Volume Accumulation (±10.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$43.51+6.2% Next Q
Q2 (-2Q)
68
Grade B-$46.22+8.8% Next Q
Q3 (-1Q)
70
Grade B$50.31-2.6% Next Q
Current
73
Grade B$49.00+7.1% Hist 90D α
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VCYT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, VCYT faces multiple-compression risk if 63.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 63x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 67.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($44.95) or 200D SMA ($42.97) invalidates the momentum regime and cuts Target Base ($52.31) toward Bear Floor ($40.18).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCYT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VCYT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 73%NO 27%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your VCYT Position Size: $10,000

Shares at $49.00: 204.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $40.18
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $52.31
$10,676
+$676 (+6.8%)
12M Bull Case BreakoutTarget $63.96
$13,053
+$3,053 (+30.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$5474%A
Goldman SachsSector Coverage LeadBUY$6069%B
JP MorganUS Large-Cap ResearchHOLD$4658%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCYT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VCYT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.49%▼ DESCENDING CHANNEL
2026-11-03O $52.17H $52.17L $49.00C $49.00VOL 1.02M
RES: $51.93SUP: $33.13SMA50: $44.95SMA200: $42.97
$62.92$54.60$46.27$37.95$29.63RES $51.93SUP $33.13$49.002026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCYT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCYT Butterfly Map → + Track VCYT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
42.9%/yr Implied 5Y Growth

vs. +16.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VCYT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCYT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCYT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCYT)

Health Care Rank #49 of 1015 ⚔️ CDNA vs VCYT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCYT vs. CDNA, CELC, CON, BLLN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Veracyte Inc. (VCYT) ranks #49 by composite RQD confidence (73/100, grade B) and #181 by equity capitalization ($4.02B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. VCYT currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VCYT ACTIVE
Veracyte Inc.
B 73/100 63.2x 70.1% 4.6% -2.02% $4.02B Benchmark Subject
CDNA
CareDx Inc.
B- 71/100 — — -8.2% -1.75% $4.59B /cdna-vs-vcyt →
CELC
Celcuity Inc.
E 31/100 — — -35.0% -2.98% $3.38B /celc-vs-vcyt →
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x — 19.7% -0.12% $5.15B /con-vs-vcyt →
BLLN
BillionToOne Inc.
B- 70/100 — 68.3% 2.9% -2.57% $5.35B /blln-vs-vcyt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001384101 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Veracyte Inc. (VCYT) reported GAAP revenue of $517.1M (+16.0% vs. FY2024 revenue of $445.8M , and +43.2% cumulative change since FY2023) , GAAP net income of $66.4M, operating cash flow of $136.3M, and free cash flow of $126.6M (+98.5% YoY). On the balance sheet, VCYT closed FY2025 with $1.41B in total assets against $43.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $517.1M $66.4M $136.3M $126.6M $1.41B $43.4M
FY2024 (FY) 2024-12-31 $445.8M $24.1M $75.1M $63.8M $1.30B $55.8M
FY2023 (FY) 2023-12-31 $361.1M -$74.4M $44.2M $28.0M $2.31B $539.8M

3. VCYT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $49.00 (-2.02% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, VCYT ranks #49 in composite RQD confidence.

How does VCYT compare to CDNA and CELC in the Health Care sector?

Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCYT?

Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCYT trading relative to its 50-day, 200-day, and 52-week technical levels?

VCYT last traded at $49.00 (-2.02% on volume of 1,150,365 shares), positioning the stock +9.01% above its 50-day simple moving average ($44.95) and +14.03% above its 200-day simple moving average ($42.97). Across its 52-week range of $29.45 to $60.91, VCYT sits at the 62.1% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.6% ($43.81 to $54.19).

Direct Sub-Reports: VCYT RQD Cockpit VCYT 12M Forecast VCYT Earnings & Move VCYT Dividends & DRIP VCYT Insiders & 13F VCYT Whale Options VCYT Profit Sankey VCYT News & Why
ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

VCYT — Veracyte Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Veracyte Inc. (VCYT) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $49.00 (-2.02% 1D, market capitalization $4.02B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 4.6%, gross margin of 70.1%, operating margin of 11.2%, and free cash flow yield of 3.02%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 9/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Veracyte Inc. (VCYT) is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Veracyte Inc. (VCYT) reported $517.1M in annual revenue (up from $445.8M in FY2024, +16.0% YoY) and $66.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($361.1M revenue, -$74.4M net income) through FY2025, VCYT scaled operating cash flow to $136.3M and free cash flow to $126.6M, backed by $1.41B in total assets against $43.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $29.45 – $60.91 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 63.2x trailing P/E and 58.7x EV/EBITDA against 11.2% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), VCYT carries a macro regime beta of 1.08 and gross margin of 70.1%.

  • Key Question #1: Can VCYT sustain or expand its 11.2% operating margin and 4.6% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $517.1M and free cash flow of $126.6M, how will capital allocation balance growth reinvestment against $43.4M in total debt?
  • Key Question #3: How sensitive is VCYT's 53.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

VCYT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Veracyte Inc. (VCYT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VCYT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VCYT Bull vs. Bear Conversation Board — What's Your Call at $49.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VCYT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VCYT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $63.51 (+27.0%)
📌 Pinned Debate

Forensic balance sheet is strong (Altman Z 26, Piotroski F 9/9, Debt/Equity 0.03) and debt fell from $539.8M to $43.4M over FY 2023–FY

Forensic balance sheet is strong (Altman Z 26, Piotroski F 9/9, Debt/Equity 0.03) and debt fell from $539.8M to $43.4M over FY 2023–FY 2025.. When you look under the hood at VCYT, Fundamental Cash Engine is 14/20 with 70.1% gross margins and 4.6% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $60.91. My 12M target is $63.51.

EarningsSniper 🐂 BULL

@ShortSeller_Dan Shorting a 16/20 institutional whale-flow stock at $50.01 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $37.51 (-25.0%)
Spot @ $50.01

Valuation is demanding at 63.2 P/E (TTM) and 58.7 EV/EBITDA against a 4.6% ROIC and weak insider-conviction pillar (11/20).

Careful chasing VCYT at $50.01. Valuation is demanding at 63.2 P/E (TTM) and 58.7 EV/EBITDA against a 4.6% ROIC and weak insider-conviction pillar (11/20).. Gross margin is 70.1%, but operating margin is 11.2%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $37.51 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%